Last Updated : January 18, 2017
Details
FilesProject Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0836-000
Question
- What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with rheumatoid arthritis?
- What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with ankylosing spondylitis?
- What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with plaque psoriasis?
- What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with Crohn’s Disease?
- What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with ulcerative colitis?
- What is the clinical effectiveness and safety of switching from innovator infliximab to subsequent entry infliximab for patients with psoriatic arthritis?
- What is the cost-effectiveness of switching from innovator infliximab to subsequent entry infliximab?
- What are the evidence-based guidelines regarding switching from innovator infliximab to subsequent entry infliximab?
Files
Last Updated : January 18, 2017